HK Stock Market Move | BEIGENE (06160) rose nearly 3% and will showcase new data on its product portfolio in blood and other treatment areas at the 2025 ASCO Annual Meeting.

BEIGENE (06160) rose nearly 3%, up 2.5% at the time of publication, to 147.6 Hong Kong dollars, with a turnover of 425 million Hong Kong dollars. On the news front, on May 22nd, according to BEIGENE's official Weibo account, BEIGENE announced that it will share 23 abstracts at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois from May 30th to June 3rd, 2025, mainly including new data on the company's product combinations in the treatment of blood and solid tumors. Two abstracts have been selected for rapid oral presentations. These data also demonstrate the company's various approaches to addressing cancer and its vision to provide innovative drugs to as many patients worldwide as possible. It is worth noting that Shenwan Hongyuan Group's research report pointed out that according to the company's announcement, BEIGENE's total revenue guidance for the full year of 2025 remains at $4.9 billion to $5.3 billion, benefiting from strong expected growth due to the leading position of zebutinib in the United States and its continued expansion in Europe and other important global markets. The firm believes that the company is a rare innovative drug company with global research and sales capabilities, and its core products continue to gain volume.